Waltham-based infectious disease biotech Visterra has agreed to be acquired by Japanese drugmaker Otsuka Pharmaceutical Co. Ltd. for $430 million.
Under the deal announced on Wednesday, Visterra will become a subsidiary of Otsuka’s U.S. holding company, and will retain its staff and location in Waltham. The transaction is expected to close in the third quarter of this year.
A spokesperson said that the company now has about 50 employees.
Tokyo-based Otsuka, by contrast, has 46,000 employees globally,…
Source: Boston Biz